246
Views
81
CrossRef citations to date
0
Altmetric
Original Article

Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium

, &
Pages 1133-1140 | Accepted 17 Apr 2006, Published online: 15 May 2006
 

ABSTRACT

Objective: To compare the cyclooxygenase (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and bromfenac sodium (bromfenac).

Methods: Cyclooxygenase activity and selectivity was determined in vitro by measuring prostaglandin E2 (PGE2) production following incubation of varying concentrations of NSAID with human recombinant COX‐1 or COX‐2 and arachidonic acid. Anti-inflammatory effects were evaluated in a rabbit model in which an ocular inflammatory response was induced by intravenous injection of 10 µg/kg lipopolysaccharide (LPS). In study animals, one eye was treated with 50 µL (+/–) ketorolac 0.4% (Acular LS) or bromfenac 0.09% (Xibrom) and the other eye with 50 µL buffered saline. In control animals, both eyes were treated with vehicle. All animals were treated twice: 2 hours and 1 hour before LPS.

‡ Acular LS is a trade name of Allergan Inc, Irvine, CA, USA

§ Xibrom is a trade name of ISTA Pharmaceuticals, Irvine, CA, USA

Main outcome measures: PGE2 production in vitro, measured by enzyme immunoassay; fluorescein isothiocyanate (FITC)-dextran leakage into the anterior chamber, measured by fluorophotometry; aqueous PGE2 levels in vivo, measured by ELISA immunoassay.

Results: Ketorolac was six times more active against COX‐1 ( IC50 = 0.02 µM) than COX‐2 ( IC50 = 0.12 µM) while bromfenac was ≈ 32 times more active against COX‐2 ( IC50 = 0.0066 µM) than COX‐1 ( IC50 = 0.210 µM). In the animal model, both drugs resulted in nearly complete inhibition of FITC-dextran leakage and PGE2 production in the anterior chamber of treated eyes. There was also a 79% inhibition ( p < 0.001) of FITC-dextran leakage in the contralateral eyes of bromfenac-treated rabbits, and a 22.5% inhibition (not statistically significant) in the contralateral eyes of ketorolac-treated rabbits.

Conclusions: Ketorolac is relatively COX‐1 selective while bromfenac is potently selective for COX‐2 over COX‐1. In the animal model, both ketorolac 0.4% and bromfenac 0.09% demonstrated maximal anti-inflammatory activity in treated eyes. Only bromfenac 0.09% had a significant effect on the contralateral eye, suggesting possible systemic absorption of this drug.

Notes

* A preliminary report of this study was presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), May 1–5, 2005; Fort Lauderdale, FL, USA

‡ Acular LS is a trade name of Allergan Inc, Irvine, CA, USA

§ Xibrom is a trade name of ISTA Pharmaceuticals, Irvine, CA, USA

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.